LDC1267 is primarily used in research settings as a selective inhibitor of the lysine-specific demethylase 1 (LSD1), an enzyme involved in epigenetic regulation of gene expression. Its main application lies in oncology research, where it helps modulate differentiation pathways in cancer cells, particularly in acute myeloid leukemia (AML). By blocking LSD1 activity, LDC1267 promotes the re-expression of silenced tumor suppressor genes and differentiation markers, leading to reduced proliferation and increased maturation of leukemic blasts. It is also employed as a tool compound to study chromatin remodeling and the role of epigenetic modifications in cellular development and disease progression. Due to its specificity and potency, LDC1267 supports the development of targeted epigenetic therapies and combination treatment strategies in preclinical models.